BACKGROUND: The efficacy of topical @entity230 in bullous pemphigoid (BP) was assessed by prospective therapeutic trials. Systemic corticosteroids and immunosuppressant agents are indicated in situations of failure or relapses. OBJECTIVES: To report our experience in the management of BP outside therapeutic trials focusing on the outcome of the @entity1 at 6 and 12 months, compliance and follow-up difficulties. METHODS: Monocenter retrospective study with collection of clinical, therapeutic and follow-up data after 6 and 12 months. RESULTS: Ninety-six @entity1 , mean age 84 years, 65 females, 54% had @entity16 . The initial dose of @entity6914 was 30 g/day, followed by a progressive decrease. In the first 6 months, 14% were lost to follow-up and 17.7% died; 62% were controlled with topical @entity230 alone, and 25% had adjunctive systemic treatment. Difficulties of compliance were mentioned in 34.4%, without significant difference between controlled and noncontrolled @entity1 . After 12 months, 23% were lost to follow-up and 27.1% died. The mean duration of the treatment was 11.7    8.4 months. After the stop, 18.9% of @entity1 relapsed within 3 months. CONCLUSION: We emphasize the frequent recourse to systemic treatments in the first few months, the difficulties of compliance and of follow-up in our day-to-day experience.

Management of bullous pemphigoid with topical XXXX in the clinical practice of a single center: outcome at 6 and 12 months.

@entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological impairment'] @entity6914 :: ('MESH:D002990', 'Chemical') :: ['clobetasol propionate']
@entity230 :: (MESH:D013256,Chemical) :: ['steroids']
